• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

General practice encounters following seasonal influenza vaccination as a proxy measure of early-onset adverse events

tetano

Editor, Senior Moderator
Vaccine. 2014 Mar 5. pii: S0264-410X(14)00229-1. doi: 10.1016/j.vaccine.2014.02.044. [Epub ahead of print]
General practice encounters following seasonal influenza vaccination as a proxy measure of early-onset adverse events.
Dey A1, Gidding HF2, Menzies R3, McIntyre P4.
Author information
Abstract
BACKGROUND:

In 2010, use of seasonal trivalent influenza vaccine (TIV) in children <5 years of age was suspended in Australia following reports of vaccine-related febrile convulsions. We investigated the utility of data on primary care [general practice (GP)] consultations for any reason within three days of receipt of influenza vaccine as recorded on the Australian Childhood Immunisation Register (ACIR) as a means of signal detection.
METHODS:

Data on GP consultations were obtained from Medicare Australia (Australian Government Department of Human Services) for children recorded on the ACIR as receiving either TIV or monovalent influenza vaccine. Rates of GP consultation by day following ACIR-recorded receipt of influenza vaccine were compared by year (2008-2010), vaccine type, age and region.
RESULTS:

In 2010, GP encounter rates on the day after receipt of the TIV manufactured by bioCSL (formerly CSL Biotherapies (Fluvax?) were significantly higher than both bioCSL TIVs in the previous two years [rate ratio (RR) 1.9; 95% CI: 1.7-2.2] and Sanofi Pasteur TIV, Vaxigrip? [RR 1.6, 95% CI 1.4-1.7] in 2009-2010. Encounter rates were also higher than for CSL Monovalent influenza vaccine, Panvax? [RR 1.9, 95% CI 1.7-2.2] in 2009-2010. These findings were robust to adjustment for age group (≤2, >2 years) and region (Western Australia vs other Australian states/territories).
CONCLUSIONS:

A primary care consultation on the day after vaccine receipt is a reasonable proxy for early reactogenicity and has potential for use in various settings.

Copyright ? 2014. Published by Elsevier Ltd.
KEYWORDS:

Adverse events, General practice, Influenza, Primary care

PMID:
24613527
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24613527
 
Back
Top Bottom